All News
Risk of Paternal Exposure to Anti-Rheumatic Drugs
Seminars in Arthritis and Rheumatism features a review of the effects of paternal use of antirheumatic drugs on pregnancy, specifically addressing the effects of NSAIDs, steroids, DMARDs and biologics on spermatogenesis and the effect on pregnancy outcomes and offspring.
Read ArticlemTOR Inhibition with Sirolimus Effective in Lupus
Lancet reports that 12 months of sirolimus treatment is associated with improvement in lupus disease activity presumeably by correction of pro-inflammatory T-cell activity.
Read ArticleShoe Inserts Disappoint with Plantar Heel Pain
A report from the British Journal of Sports Medicine shows that commonly used drug store shoe inserts or customized orthotics are often ineffective in managing plantar heel pain.
Read ArticleNovel Approach to Knee Osteoarthritis Pain
Geniculate artery embolization was found to dampen knee pain arising from osteoarthritis, according to interim study results presented at the 2018 annual meeting of the Society of Interventional Radiology.
Read ArticleTime to Rethink Gout as a Chronic Disease
The current issue of JAMA has a perspective article on Gout’s bad rap as dietary disease rather than the complex, chronic inflammatory disorder that is ineffectively treated in many.
Read ArticleUsing Synovial Tissue Biopsies to Develop Precision Medicine for Rheumatoid Arthritis
Researchers at Northwestern University have used ultrasound-guided tissue biopsy from the joints to analyze the genes of tissue macrophages with the hope that transcriptional profiling of synovial macrophages may be correlated with clinical parameters or drug responsiveness in rheumatoi
Read ArticleMMWR: Arthritis Prevalence Increases and Varies Widely
MMWR reports that In 2015, the number of adults with arthritis continued to increase; with marked geographic variability in arthritis estimates with gaps in arthritis management.
Read ArticleRepeat Malignancy Unlikely with Biologic Therapy
Research from the Danish biologics registry shows that the use of a biologic in patients with a history of a primary cancer does not increase the risk of a second malignant neoplasm (SMN) or mortality in rheumatoid arthritis (RA) patients.
Read ArticleThe RheumNow Week in Review - 16 March 2018
Dr. Jack Cush reviews the highlights from the news, journals and major meetings. Bigtime rheumatologic lessons with tales from intestinal crypts, the friendly skies & the hips of hockey players. Also the microbiome and lupus, benefits of ENT findings with GPA and rare risk of opportunistic infections with biologics.
Read ArticleOpportunistic Infections in RA Rare with Biologics
The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis has studied nearly 20,000 patients and observed that there is no substantially different risk of opportunistic infections between different biologics.
Read ArticleDoes Dose Escalation Help in Gout?
Contrary to expectations, dose escalation of allopurinol among patients with gout did not improve survival, a 10-year observational study found.
Read ArticleBone Marrow Edema Found in SI Joint of Athletes
New research shows that young elite athletes will not commonly manifest bone marrow edema in the SI joint following activity.
Read ArticlePlaquenil During Lupus Pregnancy Lessens Flares
A large cohort study of pregnant and non-pregnant women with systemic lupus erythematosus has shown that lupus flares are increased during pregnancy and in the 3 months follwing delivery.
Read ArticleLimited Utility of Arthroscopic Meniscal Surgery
JAMA Surgery reports that arthroscopic partial meniscectomy (APM) is still one of the most common surgeries performed, despite evidence from large trials (eg, FIDELITY study) showing that APM is no more effective than exercise and physical therapy, especially in adults over age 65 years.
Read ArticleCARES Study- More CV Deaths with Febuxostat
The CARES study was presented Monday at the American College of Cardiology meeting in Orlando and finds that while the rates of all major cardiovascular (CV) events were comparable between febuxostat or allopurinol, there were more CV deaths with febuxostat.
Read ArticleThe RheumNow Week in Review - 9 March 2018
Dr. Jack Cush reviews highlights, news and recent research published this past week on RheumNow.com. This week's report includes news on new regulatory changes, new indication for tofacitinib, the rise and deficits of opioids and the benefits of fish and bariatric surgery.
Read ArticleFDA Panel Votes to Favor High Dose Xeljanz in Ulcerative Colitis
Yesterday a FDA advisory panel voted 15-0 in favor of approving Xeljanz (tofacitinib) 10 mg bid for patients with moderate to severe ulcerative colitis.
Read ArticleBiologics in Pregnancy: Are They Safe?
Exposure to biologic therapies among women with autoimmune diseases was not associated with increased risks of preterm delivery or having small for gestational age babies, a population-based Canadian study found.
Read ArticleDSB – Safety Updates & Drug Shortages – March 2018
This edition of RheumNow's Drug Safey Bulletin includes drug safety news, FDA updates, FDA safety labeling changes and reported drug shortages.
Read ArticleOpioid Overdoses Jump 30% in 2017
The CDC released new information yesterday showing that emergency department (ED) visits for opioid overdoses rose 30% in the US from July 2016 through September 2017; in addition, those with an overdose are more likely to a repeat overdose.
Read Article